Urology Annals
About UA | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionLogin 
Urology Annals
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 42   Home Print this page  Email this page Small font size Default font size Increase font size
Year : 2019  |  Volume : 11  |  Issue : 2  |  Page : 119-125

New treatment modalities with vaccine therapy in renal cell carcinoma

1 Department of Urology, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey
2 Department of Physiology, Selcuklu Medical School, Selcuk University, Konya, Turkey

Correspondence Address:
Dr. Mehmet Giray Sonmez
Department of Urology, Meram Medical Faculty, Necmettin Erbakan University, Yunus Emre Quarter, Konya 42080
Login to access the Email id

DOI: 10.4103/UA.UA_166_17

PMID: 31040593

Rights and Permissions

The aim of implementing vaccine therapy is to activate immune response against malignant cells by overcoming the tolerance triggered by the tumor. These treatments are effective using the immune response against cancer. Not every type of cancer is suitable for vaccine therapies. For a vaccine therapy to be implemented, cancer should be immunogenic and contain tissue-specific proteins, should have a slow progression, and treatments should be feasible. For that reason, studies regarding urological cancers are mostly focused on the kidneys and the prostate. Vaccine therapies used in renal cell carcinoma (RCC) can be categorized under the following titles: autologous tumor cells, dendritic cells, genetically modified tumor cells, and protein/peptide. Although there are old studies on the implementation of vaccine therapies in RCC, researches have only been intensified recently. In addition to their effective potential for lengthening general survival, decreasing tumor burden and cancer development in long term, vaccine treatments are especially effective in metastatic RCC patients. We think that vaccine treatments would be applied more in near future since RCC are immunogenic. In this compilation, we will discuss vaccine therapies used in RCC, which urologists are not so familiar with, in the light of the up-to-date literature.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded262    
    Comments [Add]    

Recommend this journal